A Randomized, Multicenter, Open Phase II Study of Cetuximab With Docetaxel, Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC).

Trial Profile

A Randomized, Multicenter, Open Phase II Study of Cetuximab With Docetaxel, Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2013 Primary endpoint 'Objective-clinical-response-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top